Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier de Vichy
About this trial
The goal of this clinical trial is to learn if an intervention of a hospital pharmacist could help, dialysis patients managed his treatment. In a first time, the health literacy level will be assed.
The main questions it aims to answer are:
What is the impact of the clinical pharmacist intervention on the understanding level and management level of his treatment by the patient? Does the intervention of the pharmacist has an effect on the biologicals parameters of the patient? Researchers will compare a group with a pharmacist intervention VS a group without pharmacist intervention for dialysis patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient over 18 years of age
On dialysis (peritoneal dialysis, hemodialysis) for at least 3 months
Prescription for at least 5 daily medications
Patient who has not received any pharmaceutical consultation from a hospital pharmacist as part of his or her treatment for chronic renal failure.
Disqualifiers
Patient does not speak and/or understand French
Patient's cognitive state does not permit an interview
Patient not autonomous in managing his or her daily medication (e.g.: patient in nursing home)
Patient refusal
Trial design
Design model
Parallel
Treatments tested in this trial
Pharmacist intervention
BehavioralPatient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
Treatment groups
70 Participants
are divided into 2 treatment groupsGroup A: Controle ArmNo intervention 0 interventions
Group B: Intervention ArmExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Level of understanding and treatment management
Assessment of level of understanding and management of treatment using a survey based on the questionnaire validated by the French Health Authority (HAS). In order to take better account of the diversity of treatments for dialysis patients, we will use an adaptation of this questionnaire describing more precisely the patient's knowledge of treatments related to phosphocalcic metabolism and potassium. A score of 7 on this questionnaire means an excellent understanding of the treatment A score of 0 on this questionnaire means the poorest understanding of the treatment
Time frame
12 monthsSecondary outcomes
1
level of health literacy
Literacy will be assessed measured using the French version of the Short Test of Functional Health Literacy in Adults (STOFHLA). STOFHLA scale interpretation: Score 0-16: Inability to read and interpret healthcare texts Score 17-22: Problem reading and interpreting healthcare texts Score 23-36: Can read and interpret most healthcare texts
Time frame
12 months2
Assessment of patient-reported compliance with medication
The patient-reported compliance will be assed using the GIRERD questionnaire. This tool is made of 6 questions. A score of 0 mean a good compliance and a score ≥3 mean a bad compliance
Time frame
12 months3
Kalemia evolution
concentration of potassium in blood plasma
Time frame
12 months4
Phosphatemia evolution
concentration of phosphate in blood plasma
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: